These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 10556954)
1. Cyclophosphamide and paclitaxel as initial or salvage regimen for the mobilization of peripheral blood progenitor cells. Klein J; Rey P; Dansey R; Karanes C; Abella E; Cassells L; Hamm C; Flowers M; Couwlier C; Peters W; Baynes R Bone Marrow Transplant; 1999 Nov; 24(9):959-63. PubMed ID: 10556954 [TBL] [Abstract][Full Text] [Related]
2. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim. Weaver CH; Schulman KA; Buckner CD Bone Marrow Transplant; 2001 May; 27 Suppl 2():S23-9. PubMed ID: 11436117 [TBL] [Abstract][Full Text] [Related]
3. Collection of peripheral blood stem cells following administration of paclitaxel, cyclophosphamide, and filgrastim in patients with breast and ovarian cancer. Weaver CH; Schwartzberg LS; Birch R; Greco FA; Hainsworth J; Drapkin R; Campos L; Grapski R; Schwerkoske J; Lautersztain J; Hazelton B; Schnell F; Babcock W; Buckner CD Biol Blood Marrow Transplant; 1997 Jun; 3(2):83-90. PubMed ID: 9267668 [TBL] [Abstract][Full Text] [Related]
4. Stem cell mobilization with G-CSF alone in breast cancer patients: higher progenitor cell yield by delivering divided doses (2 x 5 microg/kg) compared to a single dose (1 x 10 microg/kg). Kröger N; Zeller W; Hassan HT; Krüger W; Gutensohn K; Löliger C; Zander AR Bone Marrow Transplant; 1999 Jan; 23(2):125-9. PubMed ID: 10197796 [TBL] [Abstract][Full Text] [Related]
5. Mobilization strategies for the collection of peripheral blood progenitor cells: Results from a pilot study of delayed addition G-CSF following chemotherapy and review of the literature. Jacoub JF; Suryadevara U; Pereyra V; Colón D; Fontelonga A; Mackintosh FR; Hall SW; Ascensão JL Exp Hematol; 2006 Nov; 34(11):1443-50. PubMed ID: 17046563 [TBL] [Abstract][Full Text] [Related]
6. Mobilization of hematopoietic progenitor cells with paclitaxel (taxol) as a single chemotheraupetic agent, associated with rhG-CSF. Gómez-Espuch J; Moraleda JM; Ortuño F; Lozano ML; Ayala F; Vallejo C; de Arriba F; Vicente V Bone Marrow Transplant; 2000 Feb; 25(3):231-5. PubMed ID: 10673692 [TBL] [Abstract][Full Text] [Related]
7. Ifosfamide in combination with paclitaxel or doxorubicin: regimens which effectively mobilize peripheral blood progenitor cells while demonstrating anti-tumor activity in patients with metastatic breast cancer. Prince HM; Gardyn J; Millward MJ; Rischin D; Francis P; Gates P; Chapple P; Quinn M; Juneja S; Wolf M; Januszewicz EH; Richardson G; Scarlett J; Briggs P; Brettell M; Toner GC Bone Marrow Transplant; 1999 Mar; 23(5):427-35. PubMed ID: 10100555 [TBL] [Abstract][Full Text] [Related]
8. Efficient peripheral blood stem cell mobilization with low-dose G-CSF (50 microg/m2) after salvage chemotherapy for lymphoma. Martínez C; Sureda A; Martino R; Cancelas JA; Madoz P; García J; Brunet S Bone Marrow Transplant; 1997 Nov; 20(10):855-8. PubMed ID: 9404926 [TBL] [Abstract][Full Text] [Related]
9. Efficient mobilization of peripheral blood stem cells following CAD chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma. Fruehauf S; Klaus J; Huesing J; Veldwijk MR; Buss EC; Topaly J; Seeger T; Zeller LW; Moehler T; Ho AD; Goldschmidt H Bone Marrow Transplant; 2007 Jun; 39(12):743-50. PubMed ID: 17450182 [TBL] [Abstract][Full Text] [Related]
10. Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim. Damon L; Rugo H; Tolaney S; Navarro W; Martin T; Ries C; Case D; Ault K; Linker C Biol Blood Marrow Transplant; 2006 Mar; 12(3):316-24. PubMed ID: 16503501 [TBL] [Abstract][Full Text] [Related]
11. Mobilization kinetics of peripheral blood progenitor cells after IAPVP-16 salvage chemotherapy plus G-CSF in lymphoproliferative disorders. Altés A; López R; Martino R; Martinez C; Cabezudo E; Muñoz L; Santamaría A; Perea G; Briones J; Salar A; Sureda A; Brunet S; Madoz P; Sierra J Bone Marrow Transplant; 2000 Jul; 26(2):127-32. PubMed ID: 10918421 [TBL] [Abstract][Full Text] [Related]
12. A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer. Hu WW; Long GD; Stockerl-Goldstein KE; Johnston LJ; Chao NJ; Negrin RS; Blume KG Clin Cancer Res; 1999 Nov; 5(11):3411-8. PubMed ID: 10589752 [TBL] [Abstract][Full Text] [Related]
13. Very large amounts of peripheral blood progenitor cells eliminate severe thrombocytopenia after high-dose melphalan in advanced breast cancer patients. Benedetti G; Patoia L; Giglietti A; Alessio M; Pelicci P; Grignani F Bone Marrow Transplant; 1999 Nov; 24(9):971-9. PubMed ID: 10556956 [TBL] [Abstract][Full Text] [Related]
14. ESHAP plus G-CSF as an effective peripheral blood progenitor cell mobilization regimen in pretreated non-Hodgkin's lymphoma: comparison with high-dose cyclophosphamide plus G-CSF. Lee JL; Kim S; Kim SW; Kim EK; Kim SB; Kang YK; Lee J; Kim MW; Park CJ; Chi HS; Huh J; Kim SH; Suh C Bone Marrow Transplant; 2005 Mar; 35(5):449-54. PubMed ID: 15654353 [TBL] [Abstract][Full Text] [Related]
15. Dose-intense paclitaxel, etoposide and cyclophosphamide: a safe and active regimen for tumor cytoreduction and stem cell mobilization in metastatic breast cancer. Bilgrami S; Feingold JM; Bona RD; Edwards RL; Khan AM; Rodriguez-Pinero F; Khan IA; Kazierad D; Clive J; Tutschka PJ Bone Marrow Transplant; 2000 Jan; 25(2):123-30. PubMed ID: 10673668 [TBL] [Abstract][Full Text] [Related]
16. Successful mobilization of peripheral blood stem cells after addition of ancestim (stem cell factor) in patients who had failed a prior mobilization with filgrastim (granulocyte colony-stimulating factor) alone or with chemotherapy plus filgrastim. To LB; Bashford J; Durrant S; MacMillan J; Schwarer AP; Prince HM; Gibson J; Lewis I; Swart B; Marty J; Rawling T; Ashman L; Charles S; Cohen B Bone Marrow Transplant; 2003 Mar; 31(5):371-8. PubMed ID: 12634728 [TBL] [Abstract][Full Text] [Related]
17. Reduced dose of lenograstim is as efficacious as standard dose of filgrastim for peripheral blood stem cell mobilization and transplantation: a randomized study in patients undergoing autologous peripheral stem cell transplantation. Ataergin S; Arpaci F; Turan M; Solchaga L; Cetin T; Ozturk M; Ozet A; Komurcu S; Ozturk B Am J Hematol; 2008 Aug; 83(8):644-8. PubMed ID: 18508321 [TBL] [Abstract][Full Text] [Related]
18. A randomized phase 2 study of PBPC mobilization by stem cell factor and filgrastim in heavily pretreated patients with Hodgkin's disease or non-Hodgkin's lymphoma. Stiff P; Gingrich R; Luger S; Wyres MR; Brown RA; LeMaistre CF; Perry J; Schenkein DP; List A; Mason JR; Bensinger W; Wheeler C; Freter C; Parker WRL ; Emmanouilides C Bone Marrow Transplant; 2000 Sep; 26(5):471-81. PubMed ID: 11019835 [TBL] [Abstract][Full Text] [Related]
19. A randomized study comparing filgrastim versus lenograstim versus molgramostim plus chemotherapy for peripheral blood progenitor cell mobilization. Kopf B; De Giorgi U; Vertogen B; Monti G; Molinari A; Turci D; Dazzi C; Leoni M; Tienghi A; Cariello A; Argnani M; Frassineti L; Scarpi E; Rosti G; Marangolo M Bone Marrow Transplant; 2006 Sep; 38(6):407-12. PubMed ID: 16951690 [TBL] [Abstract][Full Text] [Related]
20. A single dose of 6 or 12 mg of pegfilgrastim for peripheral blood progenitor cell mobilization results in similar yields of CD34+ progenitors in patients with multiple myeloma. Bruns I; Steidl U; Kronenwett R; Fenk R; Graef T; Rohr UP; Neumann F; Fischer J; Scheid C; Hübel K; Haas R; Kobbe G Transfusion; 2006 Feb; 46(2):180-5. PubMed ID: 16441592 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]